Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Food and Drug Administration (FDA) | FED |
Not provided
Not provided
Not provided
Participants will be <= 32 weeks gestational age (GA) neonates randomized to parenteral nutrition (PN) prepared with standard dose trace elements or to PN prepared with standard trace elements minus manganese.
Very preterm neonates <= 32+6 weeks GA receiving PN will be randomized to receive their PN prepared with standard trace elements containing 5 mcg/kg/day of manganese, or to PN prepared with no added manganese. Randomization assignment will be double masked. All participants will have whole blood manganese measurements at baseline, at 2 weeks of postnatal age, and at 8 weeks postnatal age. Because manganese is present as a contaminant in many of the ingredients used to prepare neonatal PN, this study hypothesizes that neonates randomized to no added manganese in their PN will maintain whole blood manganese concentrations above the lower limit of normal.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Standard neonatal trace elements | Active Comparator | Parenteral nutrition containing 5 mCg/kg/day manganese from "Multitrace-4 Neonatal." |
|
| Manganese-free neonatal trace elements | Experimental | Parenteral nutrition containing the same trace element doses as "Multitrace-4 Neonatal" minus manganese. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Manganese omission | Other | Participants randomized to the experimental intervention arm will not receive added manganese in their parenteral nutrition. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Whole Blood Manganese | concentration of manganese in blood | Baseline |
| Whole Blood Manganese | concentration of manganese in blood | 2 weeks of age |
| Whole Blood Manganese | concentration of manganese in blood | 8 weeks of age |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jason B Sauberan, PharmD | Sharp HealthCare | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sharp Mary Birch Hospital for Women and Newborns | San Diego | California | 92123 | United States |
All of the individual participant data collected during the trial, after deidentification.
Immediately after publication
Anyone
Not provided
Not provided
| ID | Term |
|---|---|
| D004194 | Disease |
| D006963 | Hyperphagia |
| D047928 | Premature Birth |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
Not provided
Not provided
Participants randomized to standard trace element dose in parenteral nutrition vs. omission of manganese.
Not provided
Not provided
Not provided
| 5 mCg/kg/day manganese from "Multitrace-4 Neonatal." | Other | 5 mCg/kg/day manganese from "Multitrace-4 Neonatal." |
|
| D007752 | Obstetric Labor, Premature |
| D007744 | Obstetric Labor Complications |
| D011248 | Pregnancy Complications |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |